Pacific Biosciences of California (NASDAQ:PACB) & 10x Genomics (NASDAQ:TXG) Critical Review

10x Genomics (NASDAQ:TXG – Get Free Report) and Pacific Biosciences of California (NASDAQ:PACB – Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, analyst recommendations and earnings.

Analyst Recommendations

This is a breakdown of current ratings for 10x Genomics and Pacific Biosciences of California, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
10x Genomics 1 12 5 0 2.22
Pacific Biosciences of California 2 3 0 0 1.60

10x Genomics currently has a consensus target price of $68.40, suggesting a potential upside of 17.55%. Pacific Biosciences of California has a consensus target price of $2.57, suggesting a potential upside of 30.95%. Given Pacific Biosciences of California’s higher probable upside, analysts clearly believe Pacific Biosciences of California is more favorable than 10x Genomics.

Volatility and Risk

10x Genomics has a beta of 2.03, meaning that its stock price is 103% more volatile than the S&P 500. Comparatively, Pacific Biosciences of California has a beta of 2.21, meaning that its stock price is 121% more volatile than the S&P 500.

Earnings and Valuation

This table compares 10x Genomics and Pacific Biosciences of California”s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
10x Genomics $618.58 million 12.26 -$43.54 million ($0.52) -111.90
Pacific Biosciences of California $161.39 million 3.80 -$546.38 million ($0.42) -4.67

10x Genomics has higher revenue and earnings than Pacific Biosciences of California. 10x Genomics is trading at a lower price-to-earnings ratio than Pacific Biosciences of California, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares 10x Genomics and Pacific Biosciences of California’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
10x Genomics -10.84% -8.19% -6.46%
Pacific Biosciences of California -81.31% -5,752.12% -19.52%

Insider & Institutional Ownership

84.7% of 10x Genomics shares are owned by institutional investors. 8.8% of 10x Genomics shares are owned by insiders. Comparatively, 3.7% of Pacific Biosciences of California shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

10x Genomics beats Pacific Biosciences of California on 10 of the 14 factors compared between the two stocks.

About 10x Genomics

(Get Free Report)

10x Genomics, Inc. develops technology for studying biological systems at single-cell and spatial resolution. Its instruments, consumables and software help researchers analyze gene expression and other features of cells while preserving information about their location within tissue. The company’s product platforms include Chromium for single-cell analysis, Visium for spatial gene-expression analysis and Xenium for in situ analysis of gene activity within tissue samples. Its tools are used in areas such as immunology, neuroscience, cancer research and drug discovery.

About Pacific Biosciences of California

(Get Free Report)

Pacific Biosciences of California, or PacBio, develops and sells DNA sequencing systems and related products for life science research and clinical applications. The company is known for its single-molecule real-time (SMRT) sequencing technology, which produces long reads that can help researchers study complex regions of the genome and identify genetic variations. Its portfolio includes HiFi sequencing systems such as the Revio and Vega platforms, along with instruments, consumables, software and services used to prepare, sequence and analyze genetic samples.

Receive News & Ratings for 10x Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 10x Genomics and related companies with MarketBeat.com's FREE daily email newsletter.